U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07936188) titled 'Phase 2 Study of GC4006A in Healthy Adults' on Oct. 21.
Brief Summary: The purpose of this study is to evaluate the safety and immunogenicity of the COVID-19 preventive vaccine 'GC4006A' in healthy adults aged 19 to 85 years
Study Start Date: Oct. 26
Study Type: INTERVENTIONAL
Condition:
Covid-19 Prevention
Intervention:
BIOLOGICAL: GC4006A
Intramuscular injection
BIOLOGICAL: GC4006A
Intramuscular injection
BIOLOGICAL: COMIRNATY
Intramuscular injection
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: GC Biopharma Corp
Disclaimer: Curated by HT Syndication....